Article
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
2014-01-01
Abstract excerpt
No abstract is available from the source.
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 86ba3ab5-db20-5969-86a2-0ecd04130ab2
- DOI
- 10.1186/1546-0096-12-s1-p76
- PMCID
- PMC4184312
